Mulpleta patient assistance program Patient assistance programs are typically sponsored by pharmaceutical companies and provide free or discounted medications to individuals with low income who are uninsured or under-insured and meet the eligibility criteria that vary by program.
Full Answer
What does Patient Assist mean?
Patient assistance programs (PAPs) help people with no health insurance and those who are underinsured afford medications. These programs are managed by pharmaceutical companies, nonprofits, and government agencies. PAPs may cover the full cost of medications or provide a discount.
Does Allergan have a patient assistance program?
The Allergan Patient Assistance Program (PAP) provides Allergan medicines at no cost to eligible patients. If the patient qualifies, up to a twelve-month eligibility for the requested medication(s) or device(s) is approved for shipment to the patient's licensed prescriber for dispensing.
Does reclast have a copay card?
Reclast Coupons, Copay Cards and Rebates Reclast offers may be in the form of a printable coupon, rebate, savings or copay card, trial offer, or free samples. Some offers may be printed right from a website, others require registration, completing a questionnaire, or obtaining a sample from the doctor's office.
How can I get help paying for Restasis?
If you're ready to take the first step towards obtaining assistance with the cost of your Restasis prescription, apply online or call Simplefill at 1(877)386-0206.
Who is myAbbVie assist?
myAbbVie Assist. We believe that people who need our medicines should be able to get them. That's why myAbbVie Assist provides free AbbVie medicine to qualifying patients. If you have any questions, visit the FAQs or call us at 1-800-222-6885.
What is the average cost of Reclast infusion?
Zoledronic Acid (Reclast) for OsteoporosisNameDosageApproximate cost*Zoledronic acid (Reclast)5-mg intravenous infusion over at least 15 minutes once a year$1,250Aug 15, 2008
Does Reclast cause weight gain?
Tell your doctor if you have serious side effects of Reclast including urinating less than usual or not at all; drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting, swelling, weight gain, shortness of breath, muscle spasms, numbness or tingling (especially around your mouth), ...
How long does bone pain last after Reclast?
Symptoms usually resolve within three days of onset, but resolution can take up to 7 to 14 days, and some symptoms have persisted for a longer duration.
Does Medicare pay for Reclast infusion?
Does Medicare cover Reclast and how much does it cost? Reclast is usually not covered for Medicare-eligible patients under Medicare Part D and Medicare Advantage prescription drug plans. However, it may be covered under Medicare Part B as a medical benefit.
How many years should Reclast be given?
Reclast only requires administration every year for the treatment of osteoporosis, and every two years for the prevention of osteoporosis. Reclast is available as a generic under the name zoledronic acid.
What is the generic for Reclast?
Reclast is a brand name for the generic drug zoledronic acid. It belongs to a class of osteoporosis treatments known as bisphosphonates, which help decrease bone turnover.
Is there a generic form of Reclast?
Reclast (zoledronic acid) is an expensive drug used to treat Paget's disease and osteoporosis in women. It is less popular than comparable drugs. There are currently no generic alternatives to Reclast.
How much does a free drug card save?
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
How much does Mulpleta cost?
The cost for Mulpleta oral tablet 3 mg is around $8,884 for a supply of 7 tablets, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
Is Mulpleta a generic drug?
Mulpleta is available as a brand name drug only, a generic version is not yet available. For more information, read about generic Mulpleta availability . This Mulpleta price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
What is a lusutrombopag?
Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
Can mulleta cause blood clots?
Blood clots, including blood clots in the liver, may happen in people with chronic liver disease and who take MULPLETA. You may have an increased risk of blood clots if you have certain blood clotting conditions.
Is Mulpleta a placebo controlled trial?
The efficacy of MULPLETA for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure was evaluated in 2 randomized, double-blind, placebo-controlled trials (L -PLUS 1 (N=97) and L-PLUS 2 (N=215; NCT02389621)). Patients with chronic liver disease who were undergoing an invasive procedure and had a platelet count less than 50 × 109/L were eligible to participate. Patients undergoing laparotomy, thoracotomy, open-heart surgery, craniotomy, or organ resection were excluded. Patients with a history of splenectomy, partial splenic embolization, or thrombosis and those with Child-Pugh class C liver disease, absence of hepatopetal blood flow, or a prothrombotic condition other than chronic liver disease were not allowed to participate.
Is Lusutrombopag safe for breastfeeding?
Due to the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment with MULPLETA and for at least 28 days after the last dose (see Clinical Considerations).
Is mulleta a TPO?
MULPLETA is a thrombopoietin (TPO) receptor agonist, and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists. Portal vein thrombosis was reported in 1% (2 of 171) of MULPLETA-treated patients and 1% (2 of 170) of placebo-treated patients in 3 randomized, double-blind trials and was identified post-procedure in protocol-specified imaging. The thromboses were not associated with a marked increase in platelet count.
Apply for patient financial assistance
Need help paying for treatments? We offer a fast, reliable way to get patient financial assistance. Apply for yourself or your patients today.
More information about applying for patient financial assistance
To qualify for a financial assistance program, you (or the patient you’re applying for) must:
